Systematic review of celecoxib for osteoarthritis and rheumatoid arthritis. Problems compromise review's validity

Comment

Peter Juni et al. BMJ. 2003.

. 2003 Feb 8;326(7384):334; author reply 334.

No abstract available

Figures

Are selective COX 2 inhibitors superior to traditional non steroidal anti-inflammatory drugs?
Jüni P, Rutjes AW, Dieppe PA. Jüni P, et al. BMJ. 2002 Jun 1;324(7349):1287-8. doi: 10.1136/bmj.324.7349.1287. BMJ. 2002. PMID: 12039807 Free PMC article. No abstract available.
Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials.
Deeks JJ, Smith LA, Bradley MD. Deeks JJ, et al. BMJ. 2002 Sep 21;325(7365):619. doi: 10.1136/bmj.325.7365.619. BMJ. 2002. PMID: 12242171 Free PMC article.

1. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325:619–623. . (21 September.) - PMC - PubMed
1. Silverstein FE, Faich G, Goldstein JL, Simon LS, Pincus T, Whelton A, et al. Gastrointestinal toxicity with celecoxib vs nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxib long-term arthritis safety study. JAMA. 2000;284:1247–1255. - PubMed
1. Jüni P, Rutjes AW, Dieppe P. Are selective COX 2 inhibitors superior to traditional NSAIDs? BMJ. 2002;325:163–164. . (20 July.) - PMC - PubMed
1. Jüni P, Rutjes AW, Dieppe PA. Are selective COX 2 inhibitors superior to traditional non-steroidal anti-inflammatory drugs? BMJ. 2002;324:1287–1288. - PMC - PubMed
1. Deeks JJ, Smith LA, Bradley MD. Efficacy, tolerability, and upper gastrointestinal safety of celecoxib for treatment of osteoarthritis and rheumatoid arthritis: systematic review of randomised controlled trials. BMJ. 2002;325:619–623. . (21 September.) - PMC - PubMed